logo
Plus   Neg
Share
Email

Earthport Board Recommends Shareholders Accept Increased Visa Offer

Visa International Service Association, or Bidco, a wholly-owned direct subsidiary of Visa Inc. (V), announced a recommended increased all cash offer for the entire issued and to be issued ordinary share capital of Earthport to be implemented by way of a takeover offer. The Earthport directors recommended unanimously that Earthport shareholders accept the increased Visa offer.

Under the terms of the increased Visa offer, each Earthport shareholder will be entitled to receive: for each Earthport share held 37 pence in cash. The increased Visa offer values the entire issued and to be issued ordinary share capital of Earthport at approximately 247 million pounds on a fully diluted basis.

The boards of Bidco and Earthport believe that the increased Visa offer price of 37 pence per Earthport share in cash is compelling and urge Earthport shareholders to take no action in relation to the Mastercard offer.

Sunil Sabharwal, Interim Chairman of Earthport, said: "The Board of Earthport is pleased to recommend Bidco's cash offer for Earthport which is at a 12 percent premium to the Mastercard proposal. This revised cash offer provides our shareholders with even greater value in cash for their shares."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT